You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Applied Proteomics said this week that it has closed a $28 million Series C financing round.
In March 2010, Austin, Texas-based diagnostics firm Vermillion launched sales of its OVA1 ovarian cancer test.
NEW YORK (GenomeWeb News) – Epic Sciences today announced it has completed its Series B financing round raising $13 million.
Protein biomarker diagnostics firm Astute Medical this week said it had completed a Series C financing round that raised $40.4 million.
By Adam Bonislawski
Applied Proteomics announced this week that it has appointed Peter Klemm as CEO and James Blair to its board of directors.
The company said it will use the money, which is an extension of a $26.5 million Series B round completed in May 2010, to advance and expand research, development, and validation of protein biomarker-based laboratory tests.
MBI plans to use the series B venture funding to develop its Apollo sample prep technologies.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.